Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.47 |
| ▸ | PPARD | Q03181 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585459 | 0.91 | PPARA (0.43) | PPARAPPARDLMNAMAPTFFAR4 | |
| SCHEMBL13542096 | 0.87 | PPARD (0.42) | PPARAPPARDMAPTHDAC1HDAC2 | |
| SCHEMBL3582912 | 0.85 | PPARA (0.46) | PPARAPPARDLMNAMAPTFFAR4 | |
| SCHEMBL3574319 | 0.85 | PPARD (0.49) | PPARAPPARDLMNAMAPTFFAR4 | |
| SCHEMBL3581652 | 0.83 | HRH3 (0.56) | — | |
| SCHEMBL3575728 | 0.83 | PPARD (0.45) | PPARAPPARDLMNAMAPT | |
| SCHEMBL3586169 | 0.82 | PPARA (0.43) | PPARAPPARDPPARGHDAC1HDAC2 | |
| SCHEMBL13543767 | 0.80 | CA1 (0.44) | PPARAPPARDLMNAMAPT | |
| SCHEMBL3575828 | 0.79 | PPARD (0.42) | PPARAPPARDLMNAMAPTHDAC1 | |
| SCHEMBL3581630 | 0.79 | PPARD (0.45) | PPARAPPARDHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | PPARA 1138/4885PPARD 1213/4885LMNA 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.